Pathological Mechanism and Targeted Drugs of Systemic Lupus Erythematosus
Bibliographic record
Abstract
The abnormal activation of immune system leads to a chronic immune-mediated disease called systemic lupus erythematosus (SLE) in general that attacks the organs of human. In the past, clinical practice often involved treatment with glucocorticoids combined with immunosuppressants. However, many patients still fail to achieve a state of low lupus disease activity (LLDAS) and are also plagued by adverse reactions such as osteoporosis, infections, and premature ovarian failure. Therefore, there is an urgent need for safer treatment regimens with fewer side effects. In recent years, with the development of knowledge into the pathology of SLE, phenomena such as aberrant B cell activation and deregulation of type I interferon (IFN-α) have been observed., providing directions for targeted therapy. Through comparative literature analysis, this article reviews the latest progress in mechanism-related studies involving B cells and IFN-α in SLE, as well as the research and development of targeted drugs. It covers aspects such as B cell-targeted therapy (e.g., telitacicept), IFN-α blockade (e.g., anifrolumab), JAK inhibition (e.g., baricitinib), and IL-6 receptor antagonism (e.g., tocilizumab). It summarizes the mechanisms of action, treatment strategies, clinical applications, and limitations of various new targeted drugs, aiming to provide a reference for personalized management and treatment strategies for SLE.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".